Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: June 3, 2019

Top 20 Shareholders, 31 May 2019

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard June 3, 2019

Top_Holders_Report (22)

Recent Articles

GMP Manufacture for Phase 2 Canine Trials
June 4, 2019
Top 20 Shareholders, 31 May 2019
June 3, 2019
25 kg of GMP Monepantel from Elanco
May 8, 2019
30 April, Top 20 Shareholders
May 6, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

PharmAust starts tablet production for Phase 2 cancer trials following the nine-day canine safety study that demonstrated excellent tolerance of Monepantel in healthy beagle dogs.
https://t.co/iBJgo0b4He

Reply on Twitter Retweet on Twitter3 Like on Twitter8 Twitter

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions